New Delhi: An experimental mRNA cancer vaccine developed by Moderna Inc and Merck & Co cut the risk of death or recurrence of the most deadly skin cancer by 44 percent compared with Merck‘s immunotherapy Keytruda alone, U.S. researchers reported at a medical meeting on Sunday. The findings suggest that adding a personalized cancer vaccine […] More
Rahway: Merck, known as MSD outside the United States and Canada, and Prometheus Biosciences, Inc. have announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, has agreed to acquire Prometheus for $200.00 per share in cash for a total equity value of approximately $10.8 billion. “At Merck, we […] More
Rahway: Merck & Co Inc and Eisai Co Ltd said on Friday they were discontinuing a late-stage study of Keytruda plus Lenvima for the treatment of adults with unresectable or metastatic melanoma, as the trial did not show improvement in overall survival. The decision to discontinue the trial was based on the recommendation of an independent data […] More
Rahway: Merck, known as MSD outside of the United States and Canada, has announced the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with Padcev (enfortumab vedotin-ejfv) for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (la/mUC) who are not eligible for cisplatin-containing chemotherapy. This […] More
US: A Delaware judge on Monday dismissed Merck & Co’s lawsuit seeking to hold Bayer AG responsible for more talc-related liabilities stemming from its $14.2 billion purchase of Merck’s consumer care business in 2014. Vice Chancellor Nathan Cook of the Delaware Chancery Court said the purchase agreement “clearly and unambiguously” left Merck liable for claims related to […] More
Here you'll find all collections you've created before.
